Compare Kimberly Clark Corp (KMB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Novo Nordisk A/S — how do they compare? Kimberly Clark Corp trades at $97.94 (market cap $32.51B), while Novo Nordisk A/S trades at $38.6 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 5.1× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays the higher dividend (5.24%). Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 93 Days and Novo Nordisk A/S for 116 Days on average.
| KMB | NVO | |
|---|---|---|
Market Cap | $32.51B | $165.31B |
Volume | 6,139,913 | 11,432,838 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $63.98 |
52-Week Low | $93.05 | $35.29 |
Typical Hold Time | 93 Days | 116 Days |
Enterprise Value | $38.07B | $179.56B |
Dividend Yield | 5.24% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $97.59, up 1.15% on the day, but remains in a bearish technical trend. The stock has shown mixed earnings performance, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026, with revenue declining to $16.45 billion in 2025. The company maintains a strong dividend history, recently declaring a $1.28 payout, while navigating its pending acquisition of Kenvue and executive transitions.
KMB offers a high dividend yield near 5%, supported by 54 consecutive years of increases, but faces risks from the Kenvue integration and cash flow pressures. Analyst consensus is a 'Hold' with a $117.25 price target, suggesting moderate upside. Key risks include execution of the large acquisition and sustaining dividend payouts amid fluctuating cash flows.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
